HLTH vs VHT: Which Is the Better Pick in 2026?

Overview

HLTH and VHT are both healthcare-focused ETFs, but they pursue fundamentally different strategies. HLTH is an actively managed fund that selects companies deploying artificial intelligence across drug discovery, diagnostics, imaging, devices, and healthcare IT. VHT is a passively managed index tracker following the MSCI US Investable Market Health Care 25/50 Index, holding the broad U.S. healthcare market with concentration limits. The key distinction is active stock-picking around an AI thesis versus passive broad-market exposure.

How they differ

HLTH is an active strategy built on a specific secular trend—AI adoption in healthcare—while VHT holds the entire healthcare sector as defined by the MSCI index. That's the largest structural difference. On scale, VHT dwarfs HLTH: VHT has $18.3B in assets against HLTH's $2.30M, and VHT has a 20-year track record dating to 2004, while HLTH just launched in July 2026. Expense ratios reflect their approach: HLTH charges 0.75% for active management versus VHT's 0.10% for passive tracking. VHT pays a 1.25% distribution yield quarterly; HLTH does not report a distribution rate. Beta tells a risk story too—HLTH's beta of 1.086 suggests it swings slightly more than the market, while VHT's 0.57 indicates it's considerably steadier than the broader market.

Who each is best for

HLTH: Fits investors who believe AI-driven healthcare innovation will outpace the traditional healthcare market and are willing to accept higher expense ratios and smaller fund scale in exchange for concentrated exposure to that theme.

VHT: Fits investors seeking broad diversification across the entire U.S. healthcare sector with minimal costs and a longer history of published performance, and who prefer passive index exposure to active thematic bets.

Key risks to know

• Concentration in an emerging theme. HLTH's focus on AI adoption in healthcare means it excludes traditional healthcare companies and pharmaceuticals that lack AI integration. If AI-driven healthcare underperforms or hype cycles cool, the fund has no diversification buffer.

• Stage and scale risk for HLTH. With only $2.30M in AUM and a July 2026 inception, HLTH is extremely new and undercapitalized. Small funds face higher risks of closure, forced liquidations, or tracking error due to limited assets and operations.

• Active manager risk. HLTH's outperformance depends on the manager's stock-picking skill in a rapidly evolving AI landscape. Selection errors or timing mistakes in emerging healthcare AI companies can drag returns below the broader healthcare index.

• Healthcare sector cyclicality. Both funds carry sensitivity to healthcare regulation, drug approval timelines, and payer reimbursement pressure—though VHT's broader holdings spread this risk across a larger universe.

• VHT's lower beta may mask sector sensitivity. VHT's 0.57 beta reflects its size and market-cap weighting, but healthcare as a sector still moves with economic cycles, rate expectations, and regulatory headlines.

Bottom line

HLTH bets on AI as a transformative force in healthcare and charges for active management to capture that opportunity; VHT offers low-cost exposure to the entire U.S. healthcare market with a proven two-decade operating history. If you believe AI will meaningfully outpace traditional healthcare returns and can tolerate higher fees and fund immaturity, HLTH's focused strategy warrants consideration. If you prefer low costs, broad sector diversification, and a long established fund, VHT's passive approach is simpler. Neither choice predicts future results.